Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2012, Article ID 412178, 11 pages
http://dx.doi.org/10.1155/2012/412178
Research Article

Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease

1Department of Immunopharmacology, Novo Nordisk A/S, 2760 Måløv, Denmark
2Department of Medical Anatomy, The Panum Institute, University of Copenhagen, 2200 Copenhagen, Denmark
3Department of Haemophilia Biology, Novo Nordisk A/S, 2760 Måløv, Denmark

Received 13 September 2011; Revised 21 October 2011; Accepted 5 November 2011

Academic Editor: Christoph Gasche

Copyright © 2012 Thomas Lindebo Holm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Loftus, “Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences,” Gastroenterology, vol. 126, no. 6, pp. 1504–1517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Casellas, J. López-Vivancos, X. Badia, J. Vilaseca, and J. R. Malagelada, “Influence of inflammatory bowel disease on different dimensions of quality of life,” European Journal of Gastroenterology and Hepatology, vol. 13, no. 5, pp. 567–572, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Bouma and W. Strober, “The immunological and genetic basis of inflammatory bowel disease,” Nature Reviews Immunology, vol. 3, no. 7, pp. 521–533, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. G. W. Dryden, “Overview of biologic therapy for Crohn's disease,” Expert Opinion on Biological Therapy, vol. 9, no. 8, pp. 967–974, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. W. J. Sandborn, B. G. Feagan, R. N. Fedorak et al., “A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease,” Gastroenterology, vol. 135, no. 4, pp. 1130–1141, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. J. Bilsborough and J. L. Viney, “From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease,” Expert Opinion on Drug Discovery, vol. 1, no. 1, pp. 69–83, 2006. View at Publisher · View at Google Scholar
  7. D. C. Baumgart and W. J. Sandborn, “Inflammatory bowel disease: clinical aspects and established and evolving therapies,” Lancet, vol. 369, no. 9573, pp. 1641–1657, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. W. Strober, I. J. Fuss, and R. S. Blumberg, “The immunology of mucosal models of inflammation,” Annual Review of Immunology, vol. 20, pp. 495–549, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. P. J. Morrissey, K. Charrier, S. Braddy, D. Liggitt, and J. D. Watson, “CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells,” Journal of Experimental Medicine, vol. 178, no. 1, pp. 237–244, 1993. View at Google Scholar · View at Scopus
  10. F. Powrie, M. W. Leach, S. Mauze, L. B. Caddle, and R. L. Coffman, “Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice,” International Immunology, vol. 5, no. 11, pp. 1461–1471, 1993. View at Google Scholar · View at Scopus
  11. F. Powrie, M. W. Leach, S. Mauze, S. Menon, L. B. Caddle, and R. L. Coffman, “Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells,” Immunity, vol. 1, no. 7, pp. 553–562, 1994. View at Google Scholar · View at Scopus
  12. S. Hue, K. J. Maloy, B. McKensie, D. Cua, and F. Powrie, “IL-23 and not IL-12 is essential for the development of IBD,” Inflammatory Bowel Diseases, vol. 12, supplement 2, S25 pages, 2006. View at Google Scholar
  13. H. H. Uhlig and F. Powrie, “Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease,” European Journal of Immunology, vol. 39, no. 8, pp. 2021–2026, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. L. Coombes, N. J. Robinson, K. J. Maloy, H. H. Uhlig, and F. Powrie, “Regulatory T cells and intestinal homeostasis,” Immunological Reviews, vol. 204, pp. 184–194, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. Kjellev, D. Lundsgaard, S. S. Poulsen, and H. Markholst, “Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing,” International Immunopharmacology, vol. 6, no. 8, pp. 1341–1354, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. Yen, J. Cheung, H. Scheerens et al., “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1310–1316, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. Teoh, L. A. Johnson, T. Hanke, A. J. McMichael, and D. G. Jackson, “Blocking development of a CD8+ T cell response by targeting lymphatic recruitment of APC,” Journal of Immunology, vol. 182, no. 4, pp. 2425–2431, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. B. R. Lúdvíksson, W. Strober, R. Nishikomori, S. K. Hasan, and R. O. Ehrhardt, “Administration of mAb against α(E)β7 prevents and ameliorates immunization-induced colitis in IL-2(-/-) mice,” Journal of Immunology, vol. 162, no. 8, pp. 4975–4982, 1999. View at Google Scholar
  19. S. Melgar, L. Karlsson, E. Rehnstrøm et al., “Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease,” International Immunopharmacology, vol. 8, no. 6, pp. 836–844, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. N. J. Davidson, S. A. Hudak, R. E. Lesley, S. Menon, M. W. Leach, and D. M. Rennick, “IL-12, but not IFN-γ, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice,” Journal of Immunology, vol. 161, no. 6, pp. 3143–3149, 1998. View at Google Scholar · View at Scopus
  21. J. Kim, C. K. Chang, T. Hayden et al., “The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection,” Journal of Immunology, vol. 179, no. 10, pp. 6416–6420, 2007. View at Google Scholar · View at Scopus
  22. H. L. Plessner, P. L. Lin, T. Konno et al., “Neutralization of Tumor Necrosis Factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis,” Journal of Infectious Diseases, vol. 195, no. 11, pp. 1643–1650, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. S. Kang, S. M. Bloom, L. A. Norian et al., “An antibiotic-responsive mouse model of fulminant ulcerative colitis,” PLoS Medicine, vol. 5, no. 3, article e41, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. K. L. Williams, C. R. Fuller, L. A. Dieleman et al., “Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone,” Gastroenterology, vol. 120, no. 4, pp. 925–937, 2001. View at Google Scholar · View at Scopus
  25. F. Sanchez-Muñoz, A. Dominguez-Lopez, and J. K. Yamamoto-Furusho, “Role of cytokines in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4280–4288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Atreya, M. Zimmer, B. Bartsch et al., “Anti-TNF antibodies target T-cell apaotosis in inflammatory bpwel diseases via TNFR2 and intestinal CD14+ macrophages,” Gastroenterology, vol. 141, no. 6, pp. 1026–1038, 2011. View at Google Scholar
  27. W. J. Sandborn, S. B. Hanauer, S. Katz et al., “Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial,” Gastroenterology, vol. 121, no. 5, pp. 1088–1094, 2001. View at Google Scholar · View at Scopus
  28. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. Z. Liu, K. Geboes, H. Heremans et al., “Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis,” European Journal of Immunology, vol. 31, no. 5, pp. 1550–1560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. M. F. Neurath, “IL-23: a master regulator in Crohn disease,” Nature Medicine, vol. 13, no. 1, pp. 26–28, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. P. J. Mannon, I. J. Fuss, L. Mayer et al., “Anti-interleukin-12 antibody for active Crohn's disease,” New England Journal of Medicine, vol. 351, no. 20, pp. 2069–2079, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. Yamamoto, K. Yoshizaki, T. Kishimoto, and H. Ito, “IL-6 is required for the development of Th1 cell-mediated murine colitis,” Journal of Immunology, vol. 164, no. 9, pp. 4878–4882, 2000. View at Google Scholar · View at Scopus
  33. R. Atreya, J. Mudter, S. Finotto et al., “Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo,” Nature Medicine, vol. 6, no. 5, pp. 583–588, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. P. S. Linsley and S. G. Nadler, “The clinical utility of inhibiting CD28-mediated costimulation,” Immunological Reviews, vol. 229, no. 1, pp. 307–321, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. C. M. Davenport, H. A. McAdams, J. Kou et al., “Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis,” International Immunopharmacology, vol. 2, no. 5, pp. 653–672, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. http://www.bms.com/clinical_trials/results/Pages/default.aspx, 2011.
  37. D. Picarella, P. Hurlbut, J. Rottman, X. Shi, E. Butcher, and D. J. Ringler, “Monoclonal antibodies specific for β 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells,” Journal of Immunology, vol. 158, no. 5, pp. 2099–2106, 1997. View at Google Scholar · View at Scopus
  38. S. Wirtz and M. F. Neurath, “Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease,” International Journal of Colorectal Disease, vol. 15, no. 3, pp. 144–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. B. G. Feagan, G. R. Greenberg, G. Wild et al., “Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin,” New England Journal of Medicine, vol. 352, no. 24, pp. 2499–2507, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. B. G. Feagan, G. R. Greenberg, G. Wild et al., “Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1370–1377, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. D. K. Podolsky, “Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease,” Digestive Diseases, vol. 27, no. 3, pp. 366–369, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. R. R. Cima and J. H. Pemberton, “Medical and surgical management of chronic ulcerative colitis,” Archives of Surgery, vol. 140, no. 3, pp. 300–310, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. W. McDonald, B. G. Feagan, D. Jewell, J. Brynskov, E. F. Stange, and J. K. Macdonald, “Cyclosporine for induction of remission in Crohn's disease,” Cochrane Database of Systematic Reviews, no. 2, pp. CD000297–CD002005, 2005. View at Google Scholar · View at Scopus
  44. Y. Ikenoue, T. Tagami, and M. Murata, “Development and validation of a novel IL-10 deficient cell transfer model for colitis,” International Immunopharmacology, vol. 5, no. 6, pp. 993–1006, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. N. Murthy, H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim, and D. J. Sedergran, “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin,” Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1722–1734, 1993. View at Google Scholar · View at Scopus
  46. G. M. Pereira, J. F. Miller, and E. M. Shevach, “Mechanism of action of cyclosporine A in vivo. II. T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyclosporine A-resistant pathway,” Journal of Immunology, vol. 144, no. 6, pp. 2109–2116, 1990. View at Google Scholar · View at Scopus
  47. I. Motta, J. H. Colle, B. Shidani, and P. Truffa-Bachi, “Interleukin 2/interleukin 4-independent T helper cell generation during an in vitro antigenic stimulation of mouse spleen cells in the presence of cyclosporin A,” European Journal of Immunology, vol. 21, no. 3, pp. 551–557, 1991. View at Google Scholar · View at Scopus
  48. J. D. Fayen, “Multiple cytokines sharing the common receptor γ chain can induce CD154/CD40 ligand expression by human CD4+ T lymphocytes via a cyclosporin A-resistant pathway,” Immunology, vol. 104, no. 3, pp. 299–306, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Kountouras, C. Zavos, and D. Chatzopoulos, “Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease,” Journal of Cellular and Molecular Medicine, vol. 8, no. 3, pp. 317–328, 2004. View at Google Scholar · View at Scopus
  50. K. Mitsuyama and M. Sata, “Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease,” Expert Opinion on Therapeutic Targets, vol. 12, no. 3, pp. 301–312, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. H. Arndt, K. D. Palitzsch, M. B. Grisham, and D. N. Granger, “Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules,” Gastroenterology, vol. 106, no. 5, pp. 1271–1276, 1994. View at Google Scholar · View at Scopus